UJVIRA 160mg injection

UJVIRA 160mg injection is an anticancer medicine with active ingredient Trastuzumab. It is used in the treatment of HER2-positive metastatic breast cancer. It is a targeted anticancer drug that works by binding on HER2-positive cancer cells to inhibit their growth & kill them.

Dosage determined as per the overall health condition of the patient. It should be given intravenously by healthcare professional only do not self administer this injection. Don't take more than the recommended dose.​

• Metastatic breast cancer  

Side effects are undesirable symptoms that can result from any medical treatment. Like any other medicine, UJVIRA 160mg injection also causes some adverse impact on the body, most of which resolve without any medical attention.

Some common side effects include:

• Fever
• Visual disturbances
• Nose bleeds or runny nose
• Hair loss
• Dizziness
• Nail disorders
• Weight loss
• Loss of appetite
• Bruising
• Dry mouth
• Liver  inflammation
• Muscle pain
• Asthma/ lung disorders

Serious

• Heart Problems
• Allergic reactions
• Kidney problems
• Breathing difficulties

Seek medical attention in case of any unusual or severe side effects immediately

• UJVIRA 160mg is available in injection form and is advised to be taken as per the doctor's prescription. It should be administered by a doctor or experienced nurse under strict medical supervision.
• Taking this injection in the wrong way may give you severe side effects. In case of overdose, contact your healthcare provider or doctor and they will provide you with medical attention.
• Missing or overdosing will impact the overall health of the patients and may also have side effects. So, it is always advisable to follow the prescription of the doctor strictly.​
  

• UJVIRA 160mg injection is an anticancer medicine with active ingredient Trastuzumab. It is a targeted anticancer that detects HER2 protein-rich cancer cells.
• It works by detecting and attaching to those cancer cells consisting of specific proteins cancer cells to inhibit their growth & multiplication. This injection directly damages and destroys the cancer cell without harming surrounding healthy cells.​
  

• Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., ... & Blackwell, K. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. New England journal of medicine, 367(19), 1783-1791. https://pubmed.ncbi.nlm.nih.gov/23020162/
• Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., ... & Crown, J. (2011). Adjuvant trastuzumab in HER2-positive breast cancer. New England journal of medicine, 365(14), 1273-1283. https://pubmed.ncbi.nlm.nih.gov/21991949/
• Pohlmann, P. R., Mayer, I. A., & Mernaugh, R. (2009). Resistance to trastuzumab in breast cancer. Clinical cancer research, 15(24), 7479-7491. https://pubmed.ncbi.nlm.nih.gov/20008848/
• Hortobagyi, G. N. (2005). Trastuzumab in the treatment of breast cancer. New England Journal of Medicine, 353(16), 1734-1736. https://pubmed.ncbi.nlm.nih.gov/16236745/
• Maximiano, S., Magalhaes, P., Guerreiro, M. P., & Morgado, M. (2016). Trastuzumab in the treatment of breast cancer. BioDrugs, 30(2), 75-86. https://pubmed.ncbi.nlm.nih.gov/26892619/
• Boekhout, A. H., Beijnen, J. H., & Schellens, J. H. (2011). Trastuzumab. The oncologist, 16(6), 800-810.